Several Wall Street analysts on Friday increased their sales forecasts for Avastin, which many now believe will soon surpass $2 billion in annual sales. JP Morgan Securities Inc., for instance, raised its sales estimates of the drug to $1.6 billion from previous forecasts of $1.3 billion for 2006. It said it expects sales to reach $2.6 billion by 2007 (http://biz.yahoo.com/ap/050415/genentech_avastin.htm...).